Communication Address:
Solara Active Pharma Sciences Limited
Batra Centre
No. 28. Sardar Patel Road. Post Box 2630
Guindy. Chennai - 600 032. India
Tel : +91 44 43446700. 22207500
Fax : +91 44 22350278
E-mail : investors@solara.com
www.solara.co.in

April 2, 2020

The BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400 001

Scrip Code: 541540

The National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: SOLARA

Dear Sir / Madam,

Sub: Announcement under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

We are enclosing herewith a press release issued by the Company titled:

"Updates on Ranitidine Hydrochloride API"

Thanking you,

Yours faithfully,
For Solara Active Pharma Sciences Limited

S. Murali Krishna
Company Secretary

Encl:- as above

PRESS **RELEASE**

FOR IMMEDIATE CIRCULATION

SOLARA
Active Pharma Sciences

WWW.SOLARA.CO.IN | BSE:541540 NSE: SOLARA BLOOMBERG: SOLARA: IN | SECTOR: PHARMACEUTICALS

Solara shares new updates on Ranitidine Hydrochloride API

- **USFDA published a statement requesting removal of all Ranitidine Products from the market immediately**
- **A new development in the ongoing investigation of a contaminant known as N-Nitrosodimethylamine (NDMA) in Ranitidine medications**

Bangalore, India – April 02, 2020:

Solara Active Pharma Sciences Ltd (Solara) (NSE: SOLARA; BSE: 541540) today shared updates on its Ranitidine API as USFDA publishes a statement on April 1, 2020[1], requesting all finished dosage formulations manufacturers to withdraw prescription and over-the-counter (OTC) Ranitidine drugs in all dosage formats from the US market immediately.

As per USFDA's statement, the agency has determined that the NDMA impurity in some Ranitidine formulation products increases over time and when stored at higher than room temperatures it may result in consumer exposure to unacceptable levels of NDMA impurity. As a result of this immediate market withdrawal request for all Ranitidine products, **Solara has stopped further manufacturing and distribution of Ranitidine API for the US market**. The Company shall engage with its formulation partners to understand the next steps and additional data that it needs to generate for supporting their product's relaunch to the market in an extended period.

Ranitidine API is amongst its top 10 APIs for Solara and contributes ~7% to its total revenues. Solara does not foresee any significant impact on its growth trajectory and continues to maintain a positive outlook for the future.

About Solara

Solara Active Pharma Sciences Ltd (BSE-541540, NSE-SOLARA) headquartered in Bengaluru, India offers a basket of diversified, high-value Commercial APIs and Contract manufacturing services in over 75 countries. It has a manufacturing base comprising five globally compliant API facilities, with approvals including the USFDA, EU GMP and PMDA in Japan.

Investor / Analyst contact

Abhishek Singhal
Investor Relations Consultant
✉ abhishek.singhal@solara.co.in
✆ +91 99877 66968

Statutory and corporate affairs

Murali Krishna S
Raghavan. V
✉ investors@solara.co.in
✆ +91 44 4344 6700

[1] https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantac-market